BioLite

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

Retrieved on: 
Wednesday, January 3, 2024

The agreement between the Company and AiBtl placed a value of $460 ($10 per share) on such payment.

Key Points: 
  • The agreement between the Company and AiBtl placed a value of $460 ($10 per share) on such payment.
  • According to the terms of the agreement, AiBtl delivered 46M shares to the Company as the first milestone payment.
  • He continued, "After this licensing payment, AiBtl becomes a subsidiary of ABVC, which holds 57% of the consolidated shares of AiBtl; accordingly, AiBtl is now also considered a related party.
  • “We believe this milestone payment marks the beginning of ABVC's revenue generation through licensing deals and opens new avenues that could potentially increase ABVC's revenue.

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

Retrieved on: 
Thursday, November 16, 2023

The agreement has the potential of licensing income worth $467M and royalties up to $200M.

Key Points: 
  • The agreement has the potential of licensing income worth $467M and royalties up to $200M.
  • The Licensed Products for MDD and ADHD, owned by ABVC and its subsidiary BioLite, Inc., were valued at $667M by a third-party evaluation.
  • ABVC and AiBtl are determined to work to strengthen their new drug development and business collaboration.
  • "With ABVC as one of our major shareholders, holding 57% consolidated shares of AiBtl, we are proud to join the family of ABVC BioPharma.

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

Retrieved on: 
Wednesday, November 15, 2023

FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.

Key Points: 
  • FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.
  • During July 2023, the warrant exercise price was reset to $3.5 under the issuance of common stock about securities purchase agreement on July 2023.
  • During the third quarter of 2023, the Company issued to Zhonghui an aggregate of 370,000 shares of the Company's common stock at a per-share price of $20.
  • "We are delighted with our remarkable accomplishments and meaningful progress in 2023, and look forward to upcoming reports to end 2023 on a positive note," said Uttam Patil, Ph.D., Chief Executive Officer of ABVC BioPharma.

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

Retrieved on: 
Thursday, October 26, 2023

The potential license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights.

Key Points: 
  • The potential license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights.
  • The Licensed Products for MDD and ADHD, owned by ABVC and its subsidiary BioLite, Inc., were valued at $667M by a third-party evaluation.
  • ABVC and AiBtl are determined to collaborate on the global development of the Licensed Products.
  • They are also working to strengthen their new drug development and business collaboration, including technology, interoperability, and standards development.

Rachio Market Enters Second Summer Helping Customers Connect Outside Through Partner Products and Exclusive Software Integrations

Retrieved on: 
Tuesday, June 6, 2023

Rachio customers are known to be early adopters of modern, outdoor tech, and these partnerships enable them to water efficiently and/or expand their smart home ecosystem, so they can Connect Outside this summer.

Key Points: 
  • Rachio customers are known to be early adopters of modern, outdoor tech, and these partnerships enable them to water efficiently and/or expand their smart home ecosystem, so they can Connect Outside this summer.
  • "The success of our smart sprinkler controllers has established Rachio as a trusted source for high-quality and tech-forward products that help customers Connect Outside," said Kim Sentovich, Rachio's CEO.
  • Rachio has also partnered with WeatherFlow since the inception of Rachio Market to offer the Tempest Weather System , which directly integrates with Rachio watering devices.
  • Through Rachio Market's innovative product offerings and partnerships, Rachio is revolutionizing outdoor spaces, expanding the smart home ecosystem outside.

Piva Capital Strengthens Team with the Addition of Adam Lasics and the Promotion of Roxanne Tully

Retrieved on: 
Thursday, April 20, 2023

SAN FRANCISCO, April 20, 2023 /PRNewswire/ -- Piva Capital, a VC firm on a mission to back visionary founders and emerging technology companies transforming industry, today announced the expansion of its team with the appointment of Adam Lasics as Partner of Strategy and Operations and the promotion of Roxanne Tully to Principal.

Key Points: 
  • "What sets Piva Capital apart is our incredible team and our commitment to transforming the industry's trajectory," said Ricardo Angel, the CEO and Managing Partner at Piva Capital.
  • He brings over 20 years of experience to Piva Capital, having worked at the intersection of strategy, finance, and energy in complementary investing and commercial roles.
  • Before GE, Lasics spent six years with McKinsey & Company as a consultant working in multi-disciplinary teams across various industries.
  • Before joining Piva, Tully spent four years with BioLite, developing innovative consumer energy products for off-grid communities around the world.

REI Releases 2022 Impact Report and Financials, Distributes $323 Million Back to Co-op Community

Retrieved on: 
Wednesday, April 19, 2023

SEATTLE, April 19, 2023 /PRNewswire/ -- REI today released its 2022 Impact Report and financials results, closing the year with a record $3.85 billion in sales. The co-op ended the year with a strong liquidity and working capital position and continued to invest in its mission of investing in its members, employees, and the outdoors.

Key Points: 
  • REI today released its 2022 Impact Report and financials results, closing the year with a record $3.85 billion in sales.
  • In 2022, REI put an additional $50 million toward pay raises for hourly employees and delivered another $92 million toward employee retirement and bonuses.
  • Through direct advocacy programs like the Cooperative Action Network and advocacy alongside partners, REI embraced the power of its community to take action in 2022.
  • REI welcomed 1.3 million members in 2022, bringing its total member count to 23 million lifetime members.

Spark+ Provides Inventory Financing to East African Last-mile Distributor

Retrieved on: 
Tuesday, January 31, 2023

LUXEMBOURG, Jan. 31, 2023 /PRNewswire-PRWeb/ -- Spark+ Africa Fund ("Spark+" or the "Fund") has provided a 2.5-year, USD 500,000 loan to Kenya-based Bidhaa Sasa (the "Company"). Bidhaa Sasa is the third investment since the Fund launched in March 2022.

Key Points: 
  • Bidhaa Sasa is a high-impact last-mile distributor offering life-improving technologies such as clean cooking solutions, on credit, to low-income consumers in rural Kenya and Uganda.
  • LUXEMBOURG, Jan. 31, 2023 /PRNewswire-PRWeb/ -- Spark+ Africa Fund ("Spark+" or the "Fund") has provided a 2.5-year, USD 500,000 loan to Kenya-based Bidhaa Sasa (the "Company").
  • Bidhaa Sasa is the third investment since the Fund launched in March 2022.
  • We look forward to enabling Bidhaa Sasa to scale-up its business and impact in East Africa during the years to come."

ABVC Biopharma Announces Letter to Shareholders

Retrieved on: 
Tuesday, September 13, 2022

FREMONT, CA, Sept. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced a letter to shareholders.

Key Points: 
  • FREMONT, CA, Sept. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced a letter to shareholders.
  • When Dr. Jiang created what is now ABVC BioPharma in 2016, he had a vision to deliver promising botanical medicines developed in the Asia Pacific region to patients in the West.
  • Each of these partnerships has been essential in spurring the growth of the ABVC pipeline.
  • Please accept my thanks and the gratitude of our entire executive team for your support and confidence in ABVC.

Midwest Custom Vehicle Builders Team with Outside Magazine for an Overland Style Adventure Truck

Retrieved on: 
Wednesday, November 3, 2021

LAS VEGAS, Nov. 3, 2021 /PRNewswire-PRWeb/ -- Custom vehicle designer, Jhan Dolphin is known for his wild custom vehicles, often paired with somewhat unusual marketing partnerships.

Key Points: 
  • LAS VEGAS, Nov. 3, 2021 /PRNewswire-PRWeb/ -- Custom vehicle designer, Jhan Dolphin is known for his wild custom vehicles, often paired with somewhat unusual marketing partnerships.
  • "Our entire build team lives an active lifestyle and loves the outdoors."
  • "So we're honored to be working with the team at Outside on this project.
  • For additional information on the project and the list of accessories and gear used to create Live Bravely, visit: http://www.JRobertMarketing.com